Day three of the Forum looks at how we can conquer disease, increase clinical trial diversity, work across borders, solve big picture problems, and work together to prepare for the whatever challenges the future may hold.

Dr. Jeff Allen, the President and CEO of Friends of Cancer Research, sits down with Dr. Peter Adamson, Global Head, Oncology Development and Pediatric Innovation, Sanofi to discuss how we can redouble our progress against cancer in the face of a pandemic.

The participants in this discussion will explore the path to progress against cancer from several different vantage points. Bringing together representatives from the patient community, the federal government, academia, and industry, the discussion will highlight the roles the public and private sector play in cancer-focused discovery, development, and delivery; hone in on the extraordinary potential inherent in breakthroughs such as immunology and CRISPR, and what those leaps in progress mean for the spectrum of cancer threats; shed light on the challenges that have rendered progress elusive against some forms of the disease such as glioblastoma and pancreatic cancer; and look at ways the horizon may be shifting (e.g. the possibility of new platforms that enable progress against multiple forms of cancer at once; the role of new clinical trial designs) as the fight to overcome cancer continues.

The roundtable participants — with audience input and a focus on the health-focused R&D workforce and workplace — will share strategies for advancing and evaluating diversity, equity, and inclusion (DEI). What are the best practices for advancing workforce and workplace DEI? Are there approaches that appeared to hold promise, but have proven ineffective? Are current definitions of DEI too broad or too narrow to promote the wellbeing of individuals across the R&D workforce? What quantitative and qualitative measures accurately capture DEI progress? What are the key attributes of a diverse, equitable and inclusive workforce and workplace?

 

Rachael Fones, Director of Government and Public Affairs at IQVIA, discusses will talk about defining success in clinical trial diversity.

 

Jenny Luray, Research!America’s Vice President for Strategy and Communications, has a conversation about opportunities for bipartisanship in Washington with Congressman Josh Gottheimer from New Jersey, co-chair of the House Problem Solvers Caucus, and former Congressman Charlie Dent, a Research!America board member, the Executive Director & Vice President, The Aspen Institute and Senior Policy Advisor, DLA Piper.

Dr. Peter Marks, Director of CBER Food and Drug Administration, and Amy Comstock Rick, a Research!America board member and President and CEO of the Food and Drug Law Institute, discuss the FDA’s outsized role in empowering safe and effective COVID-19 vaccines to reach the public in record time.

Dr. Derek Wallace, Vice President and Global Dengue Program Head, Vaccine Business Unit, Takeda Pharmaceuticals, shares his experience working on a dengue vaccine.

Dr. Tom Frieden, President and CEO of Resolve to Save Lives and former Director of the Centers for Disease Control and Prevention, sits down with Dr. Janette Nesheiwat, Medical Director at CityMD, and Fox News Medical Contributor, to discuss public health preparedness.

Olympic gymnast Laurie Hernandez discusses the importance of combating stigma around mental health issues.

Former Congressman Patrick Kennedy, Founder of the Kennedy Forum, challenges us to think bigger about combating mental illness.

What’s important in health care? Medical and public health progress that bring about safe and effective solutions; affordability for individual patients and for our healthcare system as a whole; access to the benefits of medical progress; and health equity, which depends on progress, affordability, and access, are certainly cornerstones of an effective health care system. Looking at prescription drugs as one piece of the health care puzzle, this interactive roundtable discussion will explore the challenges, imperatives, and options for simultaneously advancing progress, affordability, access, and equity.

You can find a comprehensive list of speaker biographies here.

Day 3-Defining the Path Forward